VirTra Stock Set to Release Q2 Earnings: What's in Store?
The company delivered a trailing four-quarter average earnings surprise of 198.93%.
Let's discuss the factors that are likely to be reflected in the upcoming quarterly results.
Factors to Note Ahead of VTSI's Q2 Earnings
Revenues earned from higher sales of simulators and accessories, along with design & prototyping, can be expected to have boosted VTSI's second-quarter top-line performance.
VirTra, Inc. Price and EPS Surprise
VirTra, Inc. price-eps-surprise | VirTra, Inc. Quote
Also, the successful delivery of the company's V-XR extended reality platform, anticipated in the April-June 2025 quarter, is likely to have contributed favorably to its quarterly revenues.
In addition, VirTra's steady use of AI tools to accelerate content development must have enabled it to generate higher volumes of certified training faster than ever before, thereby attracting more customers and bolstering its operational results.
However, slower bookings witnessed by the company in recent quarters, due to delays in federal budget disbursements and a more cautious demand environment across the law enforcement and defense sectors, might have hurt both revenues and earnings in the soon-to-be-reported quarter.
On the cost side, VTSI can be expected to have witnessed a decrease in cost of sales, caused by greater operational efficiencies, along with reduced operating expenses, thanks to its efforts to lower overhead costs. This, along with solid revenue growth expectations, must have contributed favorably to its second-quarter bottom line.
However, ongoing IVAS program development and initial V-XR production runs might have added upfront costs, weighing on its profitability and thereby earnings.
Q2 Expectations for VTSI
The Zacks Consensus Estimate for revenues is pegged at $6.38 million, indicating a 5.1% rise from the year-ago quarter's reported figure.
The Zacks Consensus Estimate for earnings is pegged at 3 cents per share, which indicates a decline of 72.7% from the prior-year reported figure.
What the Zacks Model Unveils for VTSI
Our proven model does not conclusively predict an earnings beat for VirTra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as you will see below.
Earnings ESP: VTSI has an Earnings ESP of 0.00%. You can uncover the best stocks before they're reported with our Earnings ESP Filter.
Zacks Rank: Currently, VirTra carries a Zacks Rank of 3. You can see the complete list of today's Zacks #1 Rank stocks here.
Stocks to Consider
Below, we have mentioned players from the same sector that have the right combination of elements to beat on earnings this reporting cycle.
Archer Aviation (ACHR) is set to report second-quarter 2025 earnings on Aug. 11, 2025, after market close. It has an Earnings ESP of +2.70% and a Zacks Rank of 3 at present.
The Zacks Consensus Estimate for ACHR's earnings is pegged at a loss of 19 cents per share, indicating a year-over-year improvement from a loss of 24 cents.
Heico Corp. (HEI) is set to report fiscal third-quarter 2025 results soon. It has an Earnings ESP of +1.16% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for HEI's earnings is pegged at $1.12 per share, indicating year-over-year growth of 15.5%. The consensus estimate for sales is pegged at $1.1 billion, indicating year-over-year growth of 12.2%.
CAE (CAE) is set to report fiscal first-quarter 2026 results on Aug. 13, 2025, before market open. It has an Earnings ESP of +0.46% and a Zacks Rank of 3 at present.
The Zacks Consensus Estimate for CAE's earnings is pegged at 15 cents per share. The consensus estimate for sales is pegged at $810.1 million, indicating year-over-year growth of 3.4%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CAE Inc (CAE) : Free Stock Analysis Report
Heico Corporation (HEI) : Free Stock Analysis Report
VirTra, Inc. (VTSI) : Free Stock Analysis Report
Archer Aviation Inc. (ACHR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc. ('Vyome'), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol 'HIND.' About Vyome Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Visit us on social media: Facebook X LinkedIn Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'target,' 'believe,' 'expect,' 'will,' 'shall,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' 'forecast,' 'intend,' 'plan,' 'project,' 'outlook', and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this report regarding the merger, including the benefits of the merger, revenue opportunities, anticipated future financial and operating performance, and results, including estimates for growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vyome's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) the occurrence of any event, change, or other circumstances relating to the combined company; (b) failure to obtain the necessary consents and approvals; (c) the risk that the merger disrupts current plans and operations as a result of the announcement and consummation of the merger; (e) costs related to the merger; and (f) changes in applicable laws or regulations. Vyome cautions that the foregoing list of factors is not exhaustive. Vyome cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vyome does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Ziopharm: Q2 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Alaunos Therapeutics, Inc. (TCRT) on Thursday reported a loss of $1.1 million in its second quarter. On a per-share basis, the Houston-based company said it had a loss of 63 cents. _____
Yahoo
an hour ago
- Yahoo
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.61 per share when it actually produced a loss of $0.65, delivering a surprise of -6.56%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. MacroGenics, which belongs to the Zacks Medical - Products industry, posted revenues of $22.24 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.73%. This compares to year-ago revenues of $10.8 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. MacroGenics shares have lost about 48.9% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for MacroGenics? While MacroGenics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for MacroGenics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.40 on $26.77 million in revenues for the coming quarter and -$2.04 on $92.12 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Ayr Wellness Inc. (AYRWF), has yet to report results for the quarter ended June 2025. This company is expected to post quarterly loss of $0.29 per share in its upcoming report, which represents a year-over-year change of +14.7%. The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. Ayr Wellness Inc.'s revenues are expected to be $111.05 million, down 5.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MacroGenics, Inc. (MGNX) : Free Stock Analysis Report Ayr Wellness Inc. (AYRWF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
